99748 20230519145357.0 doi 10.1016/j.xcrm.2020.100187 sideral 123268 ART-2021-123268 eng Dijkman, K. Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection 2021 Access copy available to the general public Unrestricted To fight tuberculosis, better vaccination strategies are needed. Live attenuated Mycobacterium tuberculosis-derived vaccine, MTBVAC, is a promising candidate in the pipeline, proven to be safe and immunogenic in humans so far. Independent studies have shown that pulmonary mucosal delivery of Bacillus Calmette-Guérin (BCG), the only tuberculosis (TB) vaccine available today, confers superior protection over standard intradermal immunization. Here we demonstrate that mucosal MTBVAC is well tolerated, eliciting polyfunctional T helper type 17 cells, interleukin-10, and immunoglobulins in the airway and yielding a broader antigenic profile than BCG in rhesus macaques. Beyond our previous work, we show that local immunoglobulins, induced by MTBVAC and BCG, bind to M. tuberculosis and enhance pathogen uptake. Furthermore, after pulmonary vaccination, but not M. tuberculosis infection, local T cells expressed high levels of mucosal homing and tissue residency markers. Our data show that pulmonary MTBVAC administration has the potential to enhance its efficacy and justifies further exploration of mucosal vaccination strategies in preclinical efficacy studies. info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020 This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020 info:eu-repo/grantAgreement/EC/H2020/730964/EU/European Vaccine Research and Development Infrastructure/TRANSVAC2 This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 730964-TRANSVAC2 info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 16.988 2021 MEDICINE, RESEARCH & EXPERIMENTAL 5 / 140 = 0.036 2021 Q1 T1 CELL BIOLOGY 17 / 195 = 0.087 2021 Q1 T1 5.956 2021 Biochemistry, Genetics and Molecular Biology (miscellaneous) 2021 Q1 7.1 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Aguilo, N. Universidad de Zaragoza (orcid)0000-0001-7897-9173 Boot, C. Hofman, S.O. Sombroek, C.C. Vervenne, R.A.W. Kocken, C.H.M. Marinova, D. Universidad de Zaragoza (orcid)0000-0001-8644-120X Thole, J. Rodríguez, E. Vierboom, M.P.M. Haanstra, K.G. Puentes, E. Martin, C. Universidad de Zaragoza (orcid)0000-0003-2993-5478 Verreck, F.A.W. 1011 630 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Microbiología 1011 X Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Proy. investigación HQA 2, 1 (2021), 100187 [18 pp] Cell rep. med. Cell reports medicine 2666-3791 2088157 http://zaguan.unizar.es/record/99748/files/texto_completo.pdf Versión publicada 1139585 http://zaguan.unizar.es/record/99748/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:99748 articulos driver 2023-05-18-13:34:29 ARTICLE